Gene therapy firm Ocugen's Q1 revenue beats, extends cash runway to 2028

Ocugen

05/05/2026 13:40

Overview

US gene therapy firm's Q1 revenue beat analyst expectations

Company posted Q1 net loss per share of $0.06

Ocugen completed $115 mln convertible notes offering, extending cash runway into 2028

Outlook

Company expects to complete two Biologics License Application submissions by 2027

Ocugen plans to initiate OCU410 Phase 3 trial in Q3 2026 with potential BLA filing by 2028

Company expects cash runway to extend into 2028 after recent financing

Result Drivers

PIPELINE ADVANCEMENT - Higher research and development expenses driven by progress in late-stage clinical trials for OCU400, OCU410ST, and OCU410

CASH POSITION - Convertible notes offering and warrant exercises expected to extend cash runway into 2028 and retire higher-interest debt

Company press release: ID:nGNXZqs3j

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$1.53 mln
$540,000 (5 Analysts)
Q1 EPS
-$0.06
Q1 Net Income
-$19.18 mln
Q1 Operating Expenses
$19.37 mln
Q1 Profit From Operations
-$17.84 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Ocugen Inc is $10.00, about 440.5% above its May 4 closing price of $1.85

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)